Skip to main content
. 2015 Feb 3;4(2):e225. doi: 10.1038/mtna.2014.76

Figure 1.

Figure 1

Long-term systemic intravenous injections of the 10-vPMO cocktail. (a) Dystrophin mRNAs with exons 45–55 skipped (detected by RT-PCR) in the various muscle types 2 weeks after the last of nine systemic intravenous (i.v.) injections of 6 mg/kg 10-vPMO cocktail (0.6 mg/kg each vPMO) at 2-week intervals. (b) Immunohistochemistry with P7 antibody against dystrophin (red) in mdx52 mice after the treatment. Representative data are shown. Scale bar, 100 μm. (c) Western blotting analysis with mouse monoclonal DYS1 antibody after repeated vPMO systemic injections into mdx52 mice. Truncated dystrophin bands at ~380 kDa (upper panel) are shown in various muscles from the vPMO cocktail–treated mdx52 mice. Positive controls, 10 and 1% protein (weight/weight percentage) of the TA muscle from WT mice; negative control, TA muscle of NT mice. Myosin heavy chain (MyHC) is shown by Coomassie Brilliant Blue staining as a loading control (lower panel). Representative data from six treated mice are shown. BB, biceps brachii; BF, biceps femoris; DIA, diaphragm; GC, gastrocnemius; HRT, heart; M, 100 bp marker; NT, nontreated mdx52-TA muscle; TA, tibialis anterior; TB, triceps brachii; QUA, quadriceps; WT, wild-type C57BL/6J.